• Boan Biotech released annual report for year ended Dec. 31, 2025, highlighting expanded commercial footprint with five marketed biologics across oncology, metabolic disease, ophthalmology.
• Growth focus shifted toward new launches in second half of 2025, with dulaglutide biosimilar Boyouping cleared for China market in August 2025.
• Ophthalmology entry accelerated with aflibercept biosimilar Boyoujing authorized in China in November 2025 for wet AMD and diabetic macular edema.
• Pipeline advanced with completion of patient enrollment for China Phase 3 study of nivolumab biosimilar BA1104 in October 2025, supporting next commercialization wave.
• International strategy progressed with denosumab biosimilars BA6101 and BA1102 completing Phase 3 trials in US, Europe, Japan, with US BLA submissions targeted by mid-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260429-12136791), on April 29, 2026, and is solely responsible for the information contained therein.